Three Drug Decisions, Two Food Recalls, and Sixteen Thousand Excess Deaths
FDA targets loom for three drugs this month; two food recalls widen; EuroMOMO counts 16,000 excess heat deaths in one week.
By Dr. Asher Knippel
Three drugs are approaching their FDA decision dates in the final weeks of August, while two food-safety outbreaks are expanding across US states and European mortality monitors have published figures that put the human cost of the continent's heat emergency into stark numerical relief.
First-Ever Treatment for a Rare Bone-Fusing Disease Awaits FDA Verdict
Fibrodysplasia ossificans progressiva (FOP) is among the most debilitating rare diseases known: the body progressively lays down extra bone in soft tissue — muscles, tendons, and ligaments — gradually fusing joints until movement becomes impossible. Globally, no more than a few hundred families live with a confirmed diagnosis. This month, the FDA is expected to rule on garetosmab (Regeneron), a fully human monoclonal antibody that neutralises Activin A, the signalling protein responsible for triggering heterotopic ossification in FOP. The phase 3 OPTIMA trial — the pivotal study supporting the Biologics License Application granted priority-review status — found a 94% reduction in new bone lesions in adults with FOP-causing type I Activin receptor gene variants. If approved, garetosmab would be the first and only disease-modifying therapy for FOP, ending decades in which families had no option beyond pain management and careful joint protection.
Radioactive Drug Gains 9.8 Extra Months Without Progression in Gut-and-Pancreas Tumours
The FDA has set 28 August as the PDUFA target date to decide on 177Lu-edotreotide (ITM-11, ITM Radiopharma), submitted for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) — slow-growing but often incurable cancers arising in the digestive tract and pancreas. The drug is a radiopharmaceutical: it attaches a radioactive lutetium-177 isotope to a peptide that homes in on somatostatin receptors, which are overexpressed in most GEP-NET cells, delivering a localised radiation dose directly at the tumour while sparing surrounding tissue. In the phase 3 COMPETE trial — the largest first-line GEP-NET trial completed to date — median progression-free survival reached 23.9 months in the 177Lu-edotreotide arm versus 14.1 months with everolimus, the standard comparator, a statistically significant gain of 9.8 months. Post-hoc subgroup analyses presented at the ENETS 2026 conference confirmed similar benefit in patients with pancreatic primaries, where median PFS was 24.5 months versus 14.7 months.
One Pill May Replace Complex HIV Regimens: FDA Decision Due 27 August
Gilead Sciences is awaiting a priority-review FDA decision — PDUFA date 27 August — on a once-daily, single-tablet regimen combining bictegravir (75 mg) and lenacapavir (50 mg) for adults living with HIV who are already virologically suppressed but currently manage their infection with complex multi-tablet antiretroviral combinations. Bictegravir is an established integrase strand transfer inhibitor; lenacapavir is a capsid inhibitor, the newest mechanistic class in HIV care. The ARTISTRY-1 and ARTISTRY-2 trials enrolled 557 participants; the BIC/LEN arm maintained virological suppression at Week 48 as effectively as continuing an existing complex regimen, with no new or significant safety signals. If cleared, this would become the smallest single-tablet HIV regimen studied in virologically suppressed adults and the first designed specifically to offer simplification without abandoning a stable, undetectable baseline — an advance with direct implications for adherence and for HIV programmes in resource-limited settings across the eastern Mediterranean and beyond.
European Heat Data: 16,000 Excess Deaths Recorded in a Single Week
European mortality surveillance data published by the EuroMOMO network show more than 16,000 excess deaths across 27 EU member states during the week of 22–28 June, with roughly 14,000 of those deaths concentrated among people aged 65 and older. Excess deaths represent the gap between observed mortality and the statistically expected baseline — they function as an indirect but well-validated proxy for heat-attributable deaths across a population. The figures arrive as meteorologists forecast a new heat dome building across Iberia, southern France, Italy, and the Aegean basin into early August, with temperatures expected to exceed 40°C. Cyprus and the eastern Mediterranean remain within the affected zone. Public health authorities are urging residents to stay hydrated, avoid outdoor activity between noon and 17:00, check on elderly and isolated neighbours, and seek care immediately for signs of heat stroke — confusion, absence of sweating despite intense heat, and loss of consciousness. Heat kills at scale and almost entirely predictably; the mortality data confirm it, and preventive action now can reduce the toll in the weeks ahead.
Cyclospora Outbreak Reaches 1,947 Cases Across Nine US States
The CDC and FDA are tracking a growing multistate Cyclospora cayetanensis outbreak now affecting nine states — Illinois, Indiana, Kansas, Kentucky, Michigan, Ohio, Oklahoma, Pennsylvania, and West Virginia — with 1,947 confirmed infections and at least 98 hospitalisations. Traceback investigation links contaminated iceberg lettuce supplied by Taylor Farms de Mexico; Taylor Farms issued a voluntary recall on 17 July 2026. A parallel investigation confirmed Cyclospora in lettuce served at Taco Bell locations in five of the affected states. Cyclospora is a single-celled intestinal parasite spread by consuming produce or water contaminated with infected faeces; it causes persistent watery diarrhoea, fatigue, and nausea that can continue for weeks without treatment. Anyone who has consumed iceberg lettuce from implicated suppliers in recent weeks and develops prolonged gastrointestinal illness should consult a clinician — the infection responds well to trimethoprim-sulfamethoxazole.
Publix Expands Frozen-Blueberry Recall Over E. coli Linked to Four Hospitalisations
A second foodborne alert is running concurrently: the CDC and FDA have confirmed 12 illnesses — four requiring hospitalisation — caused by Shiga toxin-producing E. coli O145:H28, traced to frozen GreenWise-brand organic whole blueberries and whole mixed berries sold at Publix supermarkets across eight southeastern US states. On 29 July 2026, Publix expanded its voluntary recall to cover all lots of both products. Illness onset dates span May to early June; the contamination is traced to a supplier based in Chile. Shiga toxin-producing E. coli can cause severe, bloody diarrhoea and, in high-risk groups — young children, older adults, and people who are immunocompromised — may progress to haemolytic uraemic syndrome (HUS), a potentially life-threatening kidney complication. Consumers who purchased GreenWise frozen berries at Publix should not eat them; the products should be discarded immediately.
Single Football Match Raises Concussion Biomarkers in Amateur Players
Research published in Nature Medicine found that amateur football players who headed the ball during a single recreational match showed immediate, dose-dependent elevations in two established neurological injury markers — phosphorylated tau (p-Tau217) and S100B — in blood samples collected shortly after the game. The dose-response relationship (more headers correlated with higher biomarker levels) strengthens the biological plausibility of a link between routine heading and acute neurological stress, even at the recreational level and in non-professional players. The study is observational and cannot establish long-term harm from transient biomarker elevations: the clinical significance of brief rises, as distinct from the sustained elevations associated with chronic traumatic encephalopathy or dementia, remains to be determined by longitudinal follow-up. Even so, the findings add to a body of evidence already shaping heading-restriction policies in youth and amateur football — and will likely accelerate those discussions further.
The content above is journalistic reporting and does not constitute medical advice. Readers should consult a qualified clinician or pharmacist before making any change to their treatment, medication, or health routine.